MainboardGMP
LIVE
LIVE GMP
Turtlemint Fintech Solutions Lt₹+2·Anubhav Plast Ltd₹0·Avience Biomedicals Ltd₹+85·Riyaasat Lifestyle Ltd₹0·IC Electricals Co.Ltd₹0·Dhanwel Hybrid Seeds Ltd₹0·CSM Technologies Ltd₹0·Sri Priyanka Geo Commex Ltd₹0·Advit Jewels Ltd₹+55·Shreedhar Spinners Ltd₹0·Jivial Industries Ltd₹0·Waterways Leisure Tourism Ltd₹+20·Liotech Industries Ltd₹-18·Leapfrog Engineering Services Ltd₹+8·Diksha Polymers Ltd₹+5·Clay Craft India Ltd₹+47·Horizon Reclaim (India) Ltd₹+63·Susan Electricals India Ltd₹+50·Utkal Speciality Industries India Ltd₹+14·Hexagon Nutrition Ltd₹+12·Genxai Analytics Ltd₹+3·Vahh Chemicals Ltd₹+11·Turtlemint Fintech Solutions Lt₹+2·Anubhav Plast Ltd₹0·Avience Biomedicals Ltd₹+85·Riyaasat Lifestyle Ltd₹0·IC Electricals Co.Ltd₹0·Dhanwel Hybrid Seeds Ltd₹0·CSM Technologies Ltd₹0·Sri Priyanka Geo Commex Ltd₹0·Advit Jewels Ltd₹+55·Shreedhar Spinners Ltd₹0·Jivial Industries Ltd₹0·Waterways Leisure Tourism Ltd₹+20·Liotech Industries Ltd₹-18·Leapfrog Engineering Services Ltd₹+8·Diksha Polymers Ltd₹+5·Clay Craft India Ltd₹+47·Horizon Reclaim (India) Ltd₹+63·Susan Electricals India Ltd₹+50·Utkal Speciality Industries India Ltd₹+14·Hexagon Nutrition Ltd₹+12·Genxai Analytics Ltd₹+3·Vahh Chemicals Ltd₹+11·
Home IPOs Avience Biomedicals Ltd
AV
Avience Biomedicals Ltd
● OPEN NSE SME Bookbuilding IPO Fresh capital only
GREY MARKET PREMIUM
₹ + 85
+41% expected return
EST. LISTING PRICE
₹293
Issue Price: ₹ 208
Issue Price
₹208
Face Value
₹10
Lot Size
600 shares
Open Date
18 Jun 2026
Close Date
22 Jun 2026
Allotment
23 Jun 2026
Listing Date
25 Jun 2026
Exchange
NSE SME
About the Company

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.

Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.

The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.

In addition to manufacturing, the Company also act as distributors and traders of medical equipment.

The company's manufacturing unit is situated in Noida, Uttar Pradesh.

The company offers a comprehensive range of diagnostic solutions, including:

  • Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test.
  • Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit.
  • Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY.
  • Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer.
  • Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM).

As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees

Competitive Strength

  • Strong Industry Experience and Expertise.
  • Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
  • Strong distribution network across India and is growing its international footprint.
  • Cost-Effective and Affordable Solutions.
  • Stringent quality control processes and complies with ISO standards and regulatory approvals.
Objects of the Issue
Purpose Amount (₹ Cr)
Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh ₹16
Funding the working capital requirements of the Company ₹8
General Corporate Purposes
Lead Managers
Fintellectual Corporate Advisors Pvt.Ltd
Financial Summary Amount in ₹ Crore
Metric 31 Mar 2025 31 Mar 2024 31 Mar 2023
Total Assets 44 26 10
Revenue 30 17 11
PAT 5 2 1
EBITDA 8 3 1
Net Worth 21 6 4
Reserves 17 3 1
Total Borrowing 14 8 3
Key Financial Ratios
ROE
22
ROCE
17
RONW
22
PAT Margin
16
EBITDA Margin
25
Debt/Equity
1
P/BV
3
Issue Details
Total Shares Offered
961,800
Reserved for Market Maker
82,200 shares (agg. up to ₹2 Cr)
Net Offer to Public
1,371,600 shares (agg. up to ₹29 Cr)
Pre-Issue Shareholding
4,031,256 shares
Post-Issue Shareholding
5,485,056 shares
Script Code
-
UPI Mandate
IPO Analytics Dashboard
LIVE
IPO Insights
📊
Valuation
Good
IPO Strength Score
6 / 10 Moderate
0–3 Weak 3–6 Moderate 6–8 Good 8–10 Strong
Category-wise Subscription Shares offered, bid & amount
Category Sub (x) Offered Bid For
🏦 QIB 0.03 273,600 7,800
💼 NII / HNI 66.36 207,000 13,735,800
👤 Retail (RII) 58.97 481,200 28,377,600
📊 Market Maker 82,200
Σ Total 43.79 961,800 42,121,200

* Amount calculated at upper price band (₹208) ·  ** Total includes all investor categories

Application Sizing Minimum investment by category
👤 Retail Investors ?
Min. Lots 2
Shares / Lot 1,200
Min. Investment ₹249,600
💼 HNI Investors ?
Min. Lots 3
Min. Shares 1,800
Min. Investment ₹374,400
Valuation — EPS & P/E Pre & post-issue metrics
Pre-Issue EPS ?
₹ 18
Post-Issue EPS ?
₹ 13
Pre-Issue P/E ?
12 x
Post-Issue P/E ?
17 x
IPO Timeline & Key Dates
  1. 1 💳 Initiation of Refund 24 Jun 2026
  2. 2 📂 Credit of Shares to Demat 24 Jun 2026
Investor Interpretation
  • The IPO P/E of 17x reflects a good valuation relative to typical market ranges.
  • Pre-issue EPS of ₹18 compares to post-issue EPS of ₹13 after dilution.

This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.

Company Info
📍 C-11, Block-C Community Centre, Janakpuri A-3, Delhi, New Delhi, 110058
Visit Website
Registrar
Skyline Financial Services Pvt.Ltd
Check Allotment Status
Disclaimer

The information on mainboardgmp.com is provided for educational and informational purposes only.

We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.

GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.

Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.

By using this website, you acknowledge and agree that you use the content at your own risk.